Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482612 | 1.00 | TACR1 (0.64) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL6482609 | 1.00 | TACR1 (0.64) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL6481945 | 0.85 | TACR1 (0.70) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL6484645 | 0.85 | TACR1 (0.70) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL6483282 | 0.82 | TACR1 (0.75) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6483288 | 0.82 | TACR1 (0.75) | TACR1KCNH2SLC6A4 | |
| SCHEMBL6482108 | 0.81 | TACR1 (0.74) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL6482100 | 0.81 | TACR1 (0.74) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL7172737 | 0.80 | TACR1 (0.71) | TACR1KCNH2CCR2SLC6A4 | |
| SCHEMBL6483584 | 0.80 | TACR1 (0.68) | TACR1KCNH2CCR2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | TACR1 1363/4885KCNH2 595/4885CCR2 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.